Clinical trials: Immune-Related Adverse Events
Anemia, Breast Cancer
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
RATIONALE: Epoetin alfa may stimulate red blood cell production and treat anemia in patients with cancer who are receiving chemotherapy.
- Conditions
- Anemia, Breast Cancer, Chronic Myeloproliferative Disorders, Drug/Agent Toxicity by Tissue/Organ
- Trial name
- NCT00003600
- Testing
- epoetin alfa
- Where
- 21 sites in United States, Canada
- Volunteers
- 344 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Immune-Mediated Hepatitis
Checkpoint Inhibitor-induced Liver Injury
In this multi-center prospective observational study, the investigators plan to identify the incidence and risk factors for checkpoint inhibitor-induced liver injury and characterize biochemical, genetic, immunological, and…
- Trial name
- ChILI (NCT04476563)
- Testing
- Obtaining biological samples
- Where
- United Kingdom
- Volunteers
- 160 people
- Sponsor
- University of Nottingham
Lymphoma, Large B-Cell
Study Investigating the Cardiotoxicity of Anthracyclines in Patients With Diffuse Large B-Cell
All patients enrolled in the study will have to be treated with a chemo immunotherapy scheme R-CHOP with doxorubicin, with doxorubicin analogue or non pegylated liposomal anthracycline (R-COMP; Sec.
- Conditions
- Lymphoma, Large B-Cell, Diffuse Large B-Cell
- Trial name
- NCT02916316
- Testing
- R-CHOP with doxorubicin
- Where
- 18 sites in Italy
- Volunteers
- 127 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Drug/Agent Toxicity by Tissue/Organ, Lymphoma
Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma
RATIONALE: Denileukin diftitox may be able to deliver cancer-killing substances directly to T-cell lymphoma cells. Dexamethasone may decrease the side effects of denileukin diftitox.
- Trial name
- NCT00006345
- Testing
- denileukin diftitox, dexamethasone
- Where
- 11 sites in United States
- Sponsor
- Ligand Pharmaceuticals
Toxic Epidermal Necrolysis, Stevens-Johnson Syndrome
Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis
To test the ability of palifermin (a recombinant human keratinocyte growth factor) to decrease mucocutaneous injury and to promote epithelial repair in Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome-Toxic Epidermal…
- Trial name
- NCT02037347
- Testing
- Palifermin
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Brett King
Graft vs Host Disease, Congenital Aniridia
Safety and Performance Study of the ARGOS-IO System in Patients Undergoing Boston Keratoprosthesis Implantation
The ARGOS-IO pressure sensor is intended to be implanted in the human eye in combination with Boston Keratoprosthesis (BKPro) surgery and to remain in place indefinitely.
- Conditions
- Graft vs Host Disease, Congenital Aniridia, Chemical Burns, Stevens-Johnson Syndrome
- Trial name
- NCT02945176
- Testing
- ARGOS-IO system
- Where
- 2 sites in Germany
- Volunteers
- 13 people
- Sponsor
- Implandata Ophthalmic Products GmbH
Limbal Stem Cell Deficiency, Stevens-johnson Syndrome
Clinical Trial on the Effect of Autologous Oral Mucosal Epithelial Sheet Transplantation
To investigate the effect of ocular surface reconstruction and assess the safety in cultivated oral mucosal epithelial cell sheet transplantation (COMET) regarding patients with cicatricial change of ocular surface.
- Conditions
- Limbal Stem Cell Deficiency, Stevens-johnson Syndrome, Ocular Cicatricial Pemphigoid, Chemical Burn
- Trial name
- NCT02149732
- Testing
- cultivated oral mucosal epithelial sheet transplantation
- Where
- 2 sites in South Korea
- Sponsor
- Seoul National University Hospital
Perioperative Complication, Hypersensitivity
Defining ENDOtypes in Perioperative Hypersensitivity by Extensive Cellular and Molecular PHENotyping (ENDOPHEN)
Perioperative Acute Hypersensitivity (PAH) is a systemic reaction that occurs rapidly following injection of a drug during anesthesia.The HSA-PA reaction must occur within a maximum of one hour after the induction of anesthesia…
- Trial name
- ENDOPHEN (NCT04006106)
- Where
- 7 sites in France
- Volunteers
- 103 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Immune-related Adverse Event
Hyperpolarized 13C-MRI and Metabolomics for Immune-related Adverse Events
This project investigates immune-related adverse events (irAEs) in cancer patients treated with immune checkpoint inhibitors (ICIs), focusing on metabolic changes.
- Trial name
- DNP_irAE (NCT06243250)
- Testing
- Hyperpolarized 13C-MRI
- Where
- Taiwan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Non-Small Cell Lung Cancer
A Perioperative Comprehensive Diagnosis and Treatment System for Lung Cancer in the Era of Neoadjuvant Immunotherapy
The goal of this study is to develop and refine an integrated minimally invasive care pathway for resectable lung cancer in the immunotherapy era, establishing a novel precision perioperative immunotherapy paradigm encompassing…
- Trial name
- NCT07119190
- Volunteers
- 350 people
- Sponsor
- Peking University People's Hospital
Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm
Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial
This phase II trial studies how well giving siltuximab during the reintroduction (rechallenge) of immune checkpoint inhibitor (ICI) therapy works in preventing severe immune-related adverse events (irAEs) in patients with cancer…
- Trial name
- NCT06470971
- Testing
- Anti-PD-L1 Monoclonal Antibody, Anti-PD1 Monoclonal Antibody, Biopsy
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Yuanquan Yang
Immune Related Adverse Events, Colitis
ECP for Immune-related Adverse Events After Checkpoint Inhibitor Treatment
Preliminary data demonstrate that irAEs induced by immune checkpoint blockade can be successfully treated with ECP (Apostolova et al. NEJM 2020).
- Conditions
- Immune Related Adverse Events, Colitis, Hepatitis, Dermatitis
- Trial name
- ECPforIRAE (NCT05414552)
- Testing
- ECP
- Where
- Germany
- Volunteers
- 11 people
- Sponsor
- University of Freiburg
Arthritis, Arthropathy
Radiation to Treat Joint Damage Caused by Cancer Immunotherapy
This study will prospectively investigate the feasibility and safety of administering LDRT in patients with immunotherapy-induced inflammatory arthritis.
- Trial name
- NCT07478679
- Testing
- Low dose radiation therapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Chicago
Toxic Epidermal Necrolysis, Immunotherapy
New Therapeutic Target for Toxic Epidermal Necrolysis (TEN) Using Anti-CD38+ Monoclonal Antibodies.
Toxic Epidermal Necrolysis (TEN) are rare diseases that are dermatologic emergencies characterized by widespread epidermal necrosis and sloughing of skin. A hundred patients are affected each year in France.
- Conditions
- Toxic Epidermal Necrolysis, Immunotherapy, Cutaneous Adverse Drug Reactions (CADR)
- Trial name
- NET-CD38 (NCT07110662)
- Testing
- DARATUMUMAB (DARZALEX®)
- Where
- France
- Volunteers
- 9 people
- Sponsor
- Hospices Civils de Lyon
Solid Tumor
Cohort Study: Modelling Toxicity Processing in Patients Treated by Immunotherapy (MOTIVATE).
This trial is a multicentric, prospective cohort study of 150 patients aiming to model evolution of toxicity over time in patients with solid tumor and starting first cycle of Immune Checkpoint Inhibitor (ICI) treatment.
- Trial name
- MOTIVATE (NCT03447483)
- Testing
- Patients starting a treatment by ICI
- Where
- 6 sites in France
- Volunteers
- 150 people
- Sponsor
- Institut Claudius Regaud
Wilms Tumor, Neuroblastoma
Pharmacokinetic Study of Doxorubicin in Children With Cancer
Analyze pharmacokinetics of doxorubicin in children with cancer. Furthermore investigate the predictive role of troponin and natriuretic peptides for anthracycline-induced cardiotoxicity .
- Conditions
- Wilms Tumor, Neuroblastoma, Soft Tissue Sarcoma, Acute Lymphoblastic Leukemia
- Trial name
- Doxo (NCT01095926)
- Testing
- doxorubicin
- Where
- 23 sites in France, Germany and 2 more
- Volunteers
- 101 people
- Sponsor
- University Hospital Muenster
Coronary Microvascular Dysfunction, Cardiotoxicity
Effects of Immune Checkpoint Inhibitors on Coronary Microvasculature
This is an observational study that includes patients with breast cancer or non-small cell lung cancer who will be treated with immune checkpoint inhibitor (ICI) therapy.
- Conditions
- Coronary Microvascular Dysfunction, Cardiotoxicity, Breast Cancer, Lung Cancer (NSCLC)
- Trial name
- NCT06332131
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Immune-related Adverse Event, Neoadjuvant Therapy
Exploring the Treatment Duration of PD-1 Neoadjuvant Therapy in Stage II-III dMMR Rectal Cancer
This study aims to explore the optimal number of cycles of PD-1 monotherapy required at minimum, under the premise of ensuring pathological complete response (pCR) among patients with dMMR/MSI-H rectal cancer.
- Conditions
- Immune-related Adverse Event, Neoadjuvant Therapy, dMMR Colorectal Cancer
- Trial name
- NCT06613165
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Xijing Hospital
Cancer, Psychosocial Functioning
Body Composition and Psychosocial Factors in ICI-Treated Cancer Patients
Evaluation of the effects of body composition, psychosocial factors, and drug-related problems on clinical progression (such as toxicity, treatment response, and quality of life) in cancer patients treated with immune checkpoint…
- Conditions
- Cancer, Psychosocial Functioning, Treatment Side Effects, Cachexia
- Trial name
- NCT07130981
- Where
- Turkey (Türkiye)
- Volunteers
- 200 people
- Sponsor
- Hacettepe University
Coronary Artery Disease, Cardiac Disease
The CAROLE (CArdiac Related Oncologic Late Effects) Study
CAROLE seeks to evaluate the relationship between chest Radiation Therapy and coronary artery disease. The purpose of CAROLE is to check the heart health of women who received breast cancer treatments in the past and protect them…
- Conditions
- Coronary Artery Disease, Cardiac Disease, Cardiac Toxicity, Radiation
- Trial name
- CAROLE (NCT03235427)
- Where
- United States
- Volunteers
- 201 people
- Sponsor
- Northwell Health